Prevalence of multidrug-resistant uropathogens isolated from patients with urinary tract infections in a tertiary hospital in Ghana Authors: Michael Nkrumah-Appau, Eric Darko, Daniel Dzemedo Nouwati, Ishmael Tetteh, Alex Owusu-Ofori Published: 2026 ABSTRACT BackgroundMultidrug resistance (MDR) is of a major public health concern globally, with far-reaching consequences on affected populations. Urinary Tract Infections (UTI) remain one of the major infections for which antibiotics are prescribed in Ghana, and its overuse over time has raised concerns over the development of drug resistance in UTI patients. Understanding the antimicrobial resistance patterns of uropathogens is essential for informing appropriate UTI treatment and management strategies. We therefore investigated the antibiotic resistance patterns of uropathogens implicated in suspected cases of UTI in a tertiary hospital in Ghana between 2020 and 2021.MethodsA prospective cross-sectional study was conducted at the Komfo Anokye Teaching Hospital in Ghana where 357 patients with suspected UTI had their urine samples cultured for bacteria. Sociodemographic data of participants were also collected. Isolates from positive UTI cultures were subjected to antimicrobial susceptibility testing (AST) according to CLSI guidelines (2020) using the Kirby-Bauer disk diffusion method. Data obtained was analysed using Microsoft Excel, STATA and GraphPad Prism.ResultsWe found the prevalence of uncomplicated UTI to be 26.6% (n/N = 95/357); with the identified uropathogens belonging to 10 different bacterial genera. Infections were found to be more frequent in females (67.4%, n/N = 64/95) than males. The study also found Escherichia coli (21.1%, n/N = 20/95) and Enterococcus spp. (20.0%, n/N = 19/95) as the most common organisms isolated. Antimicrobial resistance was observed in all 10 species isolated, with drug resistance highest against ampicillin (85.3%) and lowest against imipenem (19.0%) antibiotics. Multidrug resistance (MDR) was detected in 83.2% of bacteria. The study showed bacteria from 96.4% of UTI cases in males were multidrug resistant (p = 0.014) with similar higher proportions in individuals of middle-to-old age.ConclusionThis study reveals high resistance of uropathogens against many commonly-used antibiotics for treating UTI in Ghana; with more than 80% being multi-drug resistant in this population. These findings are helpful in signalling the need for revised antibiotic prescription in the treatment and management of UTI. With the clinical pipeline running dry, this evidence-based study also calls for improved antimicrobial stewardship and infection prevention and control efforts in hospitals to mitigate the spread of MDR-bacteria.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12866-026-05252-9. Introduction Antimicrobial resistance (AMR), considered by the World Health Organization (WHO) as one of the top 10 global public health threats, is a major concern to global health security [1]. The consequences of AMR are dire, including limited treatment options, increased cost of healthcare, treatment failure, prolonged hospital stay and excess mortalities [2]. Unless stringent interventions are implemented, more than 10 million AMR-related annual deaths are to be expected globally by 2050. This threatens the health security of most countries especially low and middle income countries (LMICS) such as Ghana [1–4]. This is facilitated by a combination of factors such as limited resources, inadequate healthcare support systems and paucity of data to guide antibiotic use in such countries [5]. Multidrug resistance (MDR) is described as the non-susceptibility of a microorganism to at least one microbial agent in three or more structurally-unrelated, diversely-characterized, molecular target-administered antimicrobial medicines [6]. Currently, there exists an urgent threat from multidrug-resistant bacteria, which include Carbapenem-resistant Enterobacteriaceae (CRE), Carbapenem-resistant Acinetobacter baumannii, Clostridioides difficile and drug-resistant Neisseria gonorrhoeae [7]. These bacteria cause infections that are harder to treat as they become unresponsive to a wider range of antibiotics including the more potent types [8, 9]. Urinary Tract Infections (UTIs) remain one of the common infections for which antibiotics are used in treatment and for which multidrug resistance is being observed [10, 11]. The most implicated bacteria in UTIs include Escherichia coli and Staphylococcus aureus while others such as Proteus mirabilis, Pseudomonas aeruginosa, and Enterococcus faecalis have also been frequently isolated [12–14]. In Ghana, the UTIs profile do not present as any different. Previous studies from Northern Ghana have shown prevalence of UTI to be between 34 and 40%, with tertiary facilities reporting about 37% prevalence [15, 16]. Other such studies in other parts of the West African country have shown prevalence rates ranging from 23% to up to 77% [17–22]. In these studies, as with others conducted in the diaspora, E. coli, S. aureus, Proteus spp. and Pseudomonas spp have been identified to be the most predominant UTI-causing pathogens [12, 17, 20–22]. However, data on multidrug resistant uropathogens remains sparse in most Ghanaian hospitals and healthcare systems. Therefore, as part of contributing to AMR surveillance and antibiotic stewardship, this study aimed to provide current evidence of multidrug resistance in UTIs in a Ghanaian tertiary hospital, which would be helpful in ensuring proper infection management and support antimicrobial stewardship strategies in cases of UTI. Methods Study design and setting This was a quantitative, cross-sectional, hospital-based study conducted at the Microbiology Unit of the Komfo Anokye Teaching Hospital (KATH), Ghana from January 2020 to January 2021. KATH is the 2nd largest hospital in Ghana and serves as the referral hospital for many other regions [23]. KATH provides specialised care for patients in all major fields of Medicine including Obstetrics and Gynaecology, Surgery, Child Health and Internal Medicine. Ethical considerations Approval for this operational research was provided by Komfo Anokye Teaching Hospital with ethical clearance from the Committee on Human Research, Publication and Ethics (CHRPE), KNUST (CHRPE/AP/357/18). Before enrolment, the study and its objectives were clearly explained to each participant with participants who agreed to participating, providing written consent. All study procedures conformed with the principles guiding research on human samples as set out in the Declaration of Helsinki. Sampling Inferring from previously-documented prevalence rates for UTI in Ghana [17, 20, 21], using the Cochran formula, the sample size ideal for this study was determined to be 324. In the end, urine samples were collected at random from 357 patients with clinically suspected UTI, presenting at the Microbiology Unit of the Komfo Anokye Teaching Hospital. Only clean-catch, midstream urine collected in sterile urine containers were considered. Demographic characteristics (gender and age) and hospital admission status of patients from whom the isolates were obtained were documented. Determination of positive cultures/ cases of UTI Only samples that produced single bacterial species with bacterial counts of ≥ 105/ml were considered as positive for UTI. Isolates from mixed and/or contaminated growths after initial screening were excluded. This was established for diagnostic clarity; particularly for cases where polymicrobial infections could not be distinguished from contaminations. Bacterial culture, identification and isolation Upon receiving a sample, a loopful of urine was taken and plated on Chromogenic agar (CHROMagar Orientation, Heidelberg, Germany) using a 10µL inoculation loop. The plates were then cultured for 18 h at 37 °C. This was done within 1 h of receiving the sample. From the primary culture, pure isolates were collected for downstream analysis. Bacterial growth was assessed based on colony morphology and characteristic chromogenic reactions that enabled presumptive identification of uropathogens as described by the manufacturer. Bacterial colonies were identified using the chromogenic properties produced during growth [24, 25]. Distinct colonies were sub-cultured on nutrient agar for purification. To isolate the identified bacteria, 2–3 colonies of the bacteria were picked using a sterile 1µL loop and suspended in 1 ml Brain-Heart Infusion (BHI) medium. Antimicrobial susceptibility testing (AST) Identified isolates were subjected to antimicrobial susceptibility testing using the Kirby-Bauer disk diffusion method on Mueller-Hinton agar according to Clinical Laboratory Standards Institute (CLSI) 2020 guidelines [26]. These guidelines showed no major changes with regard to the tested antibiotics as per CLSI 2024 and thus maintained the significance of the test to current clinical interpretations for AST for UTI. Eight [8] key commonly used antibiotics for UTI treatment, belonging to seven [7] different antibiotic classes, were tested. These included: trimethoprim-sulfamethoxazole (SXT, 25 µg), nalidixic acid (NA, 30 µg), ciprofloxacin (CIP, 5 µg), ampicillin (AMP, 10 µg), imipenem (IMP, 10 µg), nitrofurantoin (F, 300 µg), cefuroxime (CXM, 30 µg) and gentamicin (GEN, 10 µg) [Thermo Scientific, Rotherham, UK]. Briefly, standardized bacterial suspensions equivalent to 0.5 McFarland were evenly inoculated onto the agar surface, after which antibiotic-impregnated discs were placed on the plates and incubated at 35–37 °C for 18–24 h. The resulting zones of inhibition were measured and interpreted as susceptible, intermediate, or resistant according to guidelines above-referred. Multidrug resistance was defined as resistance against one or more agent in three or more antimicrobial categories as established elsewhere [27]. The classes of the tested antibiotics are reported in Table 1 below: Table 1Classes of antibiotics tested against isolated uropathogensNo.Antibiotic classAntibiotic(s)Abbreviation1CephalosporinsCefuroximeCXM2CarbapenemsImipenemIMP3BenzylpenicillinsAmpicillinAMP4AminoglycosidesGentamicinCN5Fluoroquinolones• Ciprofloxacin• Nalidixic acid• CIP• NA6SulfonamidesTrimethoprim-sulfamethoxazoleSXT7NitrofuransNitrofurantoinF Table 1Classes of antibiotics tested against isolated uropathogensNo.Antibiotic classAntibiotic(s)Abbreviation1CephalosporinsCefuroximeCXM2CarbapenemsImipenemIMP3BenzylpenicillinsAmpicillinAMP4AminoglycosidesGentamicinCN5Fluoroquinolones• Ciprofloxacin• Nalidixic acid• CIP• NA6SulfonamidesTrimethoprim-sulfamethoxazoleSXT7NitrofuransNitrofurantoinF Classes of antibiotics tested against isolated uropathogens • Ciprofloxacin • Nalidixic acid • CIP • NA Data analysis Data was collected, analysed and visualized using Microsoft Excel version 2016 (Microsoft Corp., Redmond, Washington, USA), STATA version 15 (StataCorp LP, Texas, USA) and GraphPad Prism v.9.0.0 (GraphPad Software Inc., La Jolla, California, USA). Descriptive statistics, including frequencies and percentages, were used to describe categorical variables such as gender, age group, and other such data about patients from whom samples were obtained. Similar was also conducted to represent UTI prevalence, antibiotic susceptibility patters, and MDR. Chi-square test of independence and multivariate logistic regression was run to determine possible associations between patient demographic data and the probability of isolation of MDR bacteria. Results Demographic characteristics of population from whom samples were obtained Samples were received from 357 participants who had been clinically diagnosed with UTI. This was dominated by females (60.8%, 217/357), middle-age to aged adults (19.3, 69/357) and by individuals visiting the outpatient department (61.6%, 220/357). Suspected UTI (UTI? ) was the most common diagnosis for which urine culture was requested (65.8%, 235/357) This has been shown in Table 2 below: Table 2Demographics of participants from whom urine samples were receivedVariablean (%), bN=357(100%)Sex Female217 (60.8) Male140 (39.2)Age group (years) Paediatric (< 18)67 (18.7) Adult (18–60)217 (60.9) Elderly (> 60)73 (20.4)Hospital Admission status In-patients137 (38.4) Out-patients220 (61.6)Clinical diagnoses Diagnosed UTI5 (1.4) UTI?235 (65.8) UTI? With Others43 (12.1) Others*74 (20.7)a Number of participantsb Total number of positive cases*Others include: Anaemia, Cyesis, Dysuria, Fever, Cancer, Heart failure, HPT, CVA, etc Table 2Demographics of participants from whom urine samples were receivedVariablean (%), bN=357(100%)Sex Female217 (60.8) Male140 (39.2)Age group (years) Paediatric (< 18)67 (18.7) Adult (18–60)217 (60.9) Elderly (> 60)73 (20.4)Hospital Admission status In-patients137 (38.4) Out-patients220 (61.6)Clinical diagnoses Diagnosed UTI5 (1.4) UTI?235 (65.8) UTI? With Others43 (12.1) Others*74 (20.7)a Number of participantsb Total number of positive cases*Others include: Anaemia, Cyesis, Dysuria, Fever, Cancer, Heart failure, HPT, CVA, etc Demographics of participants from whom urine samples were received a Number of participants b Total number of positive cases *Others include: Anaemia, Cyesis, Dysuria, Fever, Cancer, Heart failure, HPT, CVA, etc Prevalence of UTI Of the 357 participant samples considered for the study, 95 tested positive for UTI, resulting in a prevalence of 26.6%. The majority of UTI cases occurred among females (67.4%) and patients attending the outpatient department (65.3%). Additionally, a higher proportion of cases was observed among elderly individuals (> 60 years) and middle-aged adults (21–40 years). This has been shown in Table 3 below: Table 3Demographic characteristics of patients positive for UTIVariablean (%), bN=95(100%)Sex Female64 (67.4) Male31 (32.6)Age group (years) Paediatric (< 18)11 (11.6) Adult (18–60)57 (60.0) Elderly (> 60)27 (28.4) 0–105 (5.3) 11–206 (6.3) 21–3014 (14.7) 31–4018 (19.0) 41–5015 (15.8) 51–6010 (10.5) > 6027 (28.4)Hospital Admission status In-patients33 (34.7) Out-patients62 (65.3)a Number of participantsb Total number of positive cases Table 3Demographic characteristics of patients positive for UTIVariablean (%), bN=95(100%)Sex Female64 (67.4) Male31 (32.6)Age group (years) Paediatric (< 18)11 (11.6) Adult (18–60)57 (60.0) Elderly (> 60)27 (28.4) 0–105 (5.3) 11–206 (6.3) 21–3014 (14.7) 31–4018 (19.0) 41–5015 (15.8) 51–6010 (10.5) > 6027 (28.4)Hospital Admission status In-patients33 (34.7) Out-patients62 (65.3)a Number of participantsb Total number of positive cases Demographic characteristics of patients positive for UTI a Number of participants b Total number of positive cases Distribution of isolated uropathogens As seen in Figs. 1 and 2 below, the 95 isolates from the positive UTI cases were of ten [10] different bacterial species with Escherichia coli being the most commonly isolated uropathogen (21.1%), followed by Enterococcus spp (20.0%) (Fig. 1). Most isolates were Gram-negative (64.21%) (Fig. 2). Fig. 1Distribution of isolated uropathogens. The x-axis of the bar chart shows the various bacteria isolated from the 95 positive samples while the y-axis shows their respective proportions (%100) Distribution of isolated uropathogens. The x-axis of the bar chart shows the various bacteria isolated from the 95 positive samples while the y-axis shows their respective proportions (%100) Fig. 2Distribution of Gram negative and Gram positive uropathogens. The x-axis shows the two Gram reactions of bacteria while the y-axis shows their respective frequencies among isolates. GP=Gram positive, GN=Gram-negative Distribution of Gram negative and Gram positive uropathogens. The x-axis shows the two Gram reactions of bacteria while the y-axis shows their respective frequencies among isolates. GP=Gram positive, GN=Gram-negative Antimicrobial resistance patterns of isolated uropathogens Isolated bacteria were most resistant to ampicillin (85.3%) with high resistance also observed against nalidixic acid (80.0%) and trimethoprim-sulfamethoxazole (62.1%) (Fig. 3). E. coli, the most prevalent uropathogen isolated, showed high resistance to nalidixic acid (90.0%), ampicillin (80.0%) and trimethoprim-sulfamethoxazole (70.0%). However, isolates were least resistant to imipenem (19.0%) (Table 4). Fig. 3Antibiotic resistance patterns of isolated uropathogens. The x-axis shows the respective antibiotics tested while the y-axis shows their respective resistance rates. AMP=Ampicillin, NA=Nalidixic acid, SXT=Trimethoprim-sulfamethoxazole, CN=Gentamicin, CIP=Ciprofloxacin, F=Nitrofurantoin, CXM=Cefuroxime, IPM=Imipenem Antibiotic resistance patterns of isolated uropathogens. The x-axis shows the respective antibiotics tested while the y-axis shows their respective resistance rates. AMP=Ampicillin, NA=Nalidixic acid, SXT=Trimethoprim-sulfamethoxazole, CN=Gentamicin, CIP=Ciprofloxacin, F=Nitrofurantoin, CXM=Cefuroxime, IPM=Imipenem Table 4Antimicrobial resistance patterns of specific uropathogensResistance to *antibiotics **n, (%)Isolates ***(N)AMPNASXTCNCIPFCXMIPMCitrobacter sp. (N = 17)15, (88.2)12, (70.6)8, (47.1)8, (47.1)9, (52.9)10, (58.8)9, (52.9)2, (11.8)E. coli (N = 20)16, (80.0)18, (90.0)14, (70.0)7, (35.0)12, (60.0)5, (25.0)10, (50.0)0, (0.0)Enterobacter sp. (N = 5)4,(80.0)4, (80.0)2, (40.0)2, (40.0)2, (40.0)4, (80.0)4, (80.0)0, (0.0)Enterococcus sp. (N = 19)15, (78.9)15, (78.9)13, (68.4)13, (68.4)9, (47.4)10, (52.6)10, (52.6)3, (15.8)Klebsiella sp. (N = 9)9, (100.0)6, (66.7)3, (33.3)8, (88.9)5, (55.6)8, (88.9)4, (44.4)1, (11.1)Proteus sp. (N = 3)1, (33.3)1, (33.3)1, (33.3)1, (33.3)1, (33.3)3, (100.0)1, (33.3)3, (100.0)P. aeruginosa (N = 7)7, (100.0)6, (85.7)6, (85.7)5, (71.4)5, (71.4)5, (71.4)4, (57.1)3, (42.9)S. agalactiae (N = 3)2, (66.7)2, (66.7)1, (33.3)3, (100.0)2, (66.7)2,(66.7)2, (66.7)0, (0.0)S. aureus (N = 11)11,(100.0)10, (90.9)10, (90.9)8, (72.7)9, (81.8)7, (63.6)7, (63.6)5, (45.5)S. saprophyticus (N = 1)1, (100.0)1, (100.0)1, (100.0)1, (100.0)1, (100.0)1, (100.0)0, (0.0)1, (100.0)*List of antibiotics tested AMP Ampicillin, NA Nalidixic acid, SXT Trimethoprim-sulfamethoxazole, CN Gentamicin, CIP Ciprofloxacin, F Nitrofurantoin, CXM Cefuroxime, IPM Imipenem**n Number of resistant isolates***N Total number of isolates Table 4Antimicrobial resistance patterns of specific uropathogensResistance to *antibiotics **n, (%)Isolates ***(N)AMPNASXTCNCIPFCXMIPMCitrobacter sp. (N = 17)15, (88.2)12, (70.6)8, (47.1)8, (47.1)9, (52.9)10, (58.8)9, (52.9)2, (11.8)E. coli (N = 20)16, (80.0)18, (90.0)14, (70.0)7, (35.0)12, (60.0)5, (25.0)10, (50.0)0, (0.0)Enterobacter sp. (N = 5)4,(80.0)4, (80.0)2, (40.0)2, (40.0)2, (40.0)4, (80.0)4, (80.0)0, (0.0)Enterococcus sp. (N = 19)15, (78.9)15, (78.9)13, (68.4)13, (68.4)9, (47.4)10, (52.6)10, (52.6)3, (15.8)Klebsiella sp. (N = 9)9, (100.0)6, (66.7)3, (33.3)8, (88.9)5, (55.6)8, (88.9)4, (44.4)1, (11.1)Proteus sp. (N = 3)1, (33.3)1, (33.3)1, (33.3)1, (33.3)1, (33.3)3, (100.0)1, (33.3)3, (100.0)P. aeruginosa (N = 7)7, (100.0)6, (85.7)6, (85.7)5, (71.4)5, (71.4)5, (71.4)4, (57.1)3, (42.9)S. agalactiae (N = 3)2, (66.7)2, (66.7)1, (33.3)3, (100.0)2, (66.7)2,(66.7)2, (66.7)0, (0.0)S. aureus (N = 11)11,(100.0)10, (90.9)10, (90.9)8, (72.7)9, (81.8)7, (63.6)7, (63.6)5, (45.5)S. saprophyticus (N = 1)1, (100.0)1, (100.0)1, (100.0)1, (100.0)1, (100.0)1, (100.0)0, (0.0)1, (100.0)*List of antibiotics tested AMP Ampicillin, NA Nalidixic acid, SXT Trimethoprim-sulfamethoxazole, CN Gentamicin, CIP Ciprofloxacin, F Nitrofurantoin, CXM Cefuroxime, IPM Imipenem**n Number of resistant isolates***N Total number of isolates Antimicrobial resistance patterns of specific uropathogens 4, (80.0) 2, (66.7) *List of antibiotics tested AMP Ampicillin, NA Nalidixic acid, SXT Trimethoprim-sulfamethoxazole, CN Gentamicin, CIP Ciprofloxacin, F Nitrofurantoin, CXM Cefuroxime, IPM Imipenem **n Number of resistant isolates ***N Total number of isolates Investigation of multidrug resistance (MDR) in isolated uropathogens We found 83.2% (79/95) of isolated uropathogens to be resistant to at least three different classes of antibiotics (Fig. 4), with an average of resistance to at least 4 antibiotics (Fig. 5). A relatively higher proportion of bacteria isolated from male UTI cases were multidrug resistant (96.8%) compared with those from female cases (76.6%), and this difference was statistically significant (p = 0.014). Also, multidrug resistant uropathogens were predominant in out-patients (p = 0.406) as well as the adult population (0.075) although not statistically significant (Table 5). Multivariate logistic regression analysis confirmed gender as a significant predictor of MDR-related UTI. Specifically, males were significantly associated with increased odds of multidrug-resistant uropathogens causing UTI (OR = 9.43, 95% CI: 1.15–77.53, p = 0.037). However, the confidence interval observed was very wide (1.15–77.53) and likely suggests a small sample size and possible instability in the estimation as likely limitations to the generalization of this finding. Also, while outpatients (OR = 2.00, p = 0.253) and age groups—elderly (OR = 3.34, p = 0.146) and paediatric (OR = 2.77, p = 0.364)—were associated with higher odds of UTI, these associations were not statistically significant. The overall model was statistically significant (p = 0.017) (Table 6). It was worth noting however, that multidrug resistance was observed in all species of bacteria isolated (Table 7). Fig. 4Prevalence of multidrug resistant uropathogens. The pie chart shows the proportions of MDR uropathogens against non-MDR uropathogens. MDR-neg=Multidrug resistance negative. MDR-pos=Multidrug resistance positive Prevalence of multidrug resistant uropathogens. The pie chart shows the proportions of MDR uropathogens against non-MDR uropathogens. MDR-neg=Multidrug resistance negative. MDR-pos=Multidrug resistance positive Fig. 5Frequency of multidrug resistant uropathogens. The x-axis shows the number of different antibiotic classes the uropathogens were resistant to while the y-axis shows the frequency of uropathogens Frequency of multidrug resistant uropathogens. The x-axis shows the number of different antibiotic classes the uropathogens were resistant to while the y-axis shows the frequency of uropathogens Table 5Proportion of multidrug resistance per participant demographicsVariableMDR-negative (n, %)MDR-positive (n, %)p-valueSex Female (n = 64)15 (23.4)49 (76.6) 0.014* Male (n = 31)1 (3.2)30 (96.8)Hospital admission status In-patient (n = 33)7 (21.2)26 (78.8) 0.406 Out-patient (n = 62)9 (14.5)53 (85.5)AgePaediatric (< 18) [n = 11]1 (9.1)10 (90.9) 0.162 Adult (18–20) [n = 57]13 (22.8)44 (77.2)Elderly (> 60) [n = 27]2 (7.4)25 (92.6)Total 16 (100.0) 79 (100.0) *Significance of comparison was determined by p-value < 0.05 Table 5Proportion of multidrug resistance per participant demographicsVariableMDR-negative (n, %)MDR-positive (n, %)p-valueSex Female (n = 64)15 (23.4)49 (76.6) 0.014* Male (n = 31)1 (3.2)30 (96.8)Hospital admission status In-patient (n = 33)7 (21.2)26 (78.8) 0.406 Out-patient (n = 62)9 (14.5)53 (85.5)AgePaediatric (< 18) [n = 11]1 (9.1)10 (90.9) 0.162 Adult (18–20) [n = 57]13 (22.8)44 (77.2)Elderly (> 60) [n = 27]2 (7.4)25 (92.6)Total 16 (100.0) 79 (100.0) *Significance of comparison was determined by p-value < 0.05 Proportion of multidrug resistance per participant demographics *Significance of comparison was determined by p-value < 0.05 Table 6Multivariate logistic regression analysis of associations between demographic variables and propensity for multidrug resistant uropathogens isolationMDR isolateOdds ratioStd. Err.zP>|z|95% C. IGender Male9.42969110.136152.09 0.037 1.15–77.53 Female Reference Admission status Out-patient1.999941.213691.140.2530.61–6.57 In-patient Reference Age group Elderly3.3358982.765371.450.1460.66–16.94 Paediatric2.766543.1042160.910.3640.31–24.95 Adult Reference _constant1.495010.76401230.790.4310.55–4.07Number of observations = 95, LR chi2 (4) = 11.99, Prob > chi2 = 0.0174, Pseudo R2 = 0.1392 Table 6Multivariate logistic regression analysis of associations between demographic variables and propensity for multidrug resistant uropathogens isolationMDR isolateOdds ratioStd. Err.zP>|z|95% C. IGender Male9.42969110.136152.09 0.037 1.15–77.53 Female Reference Admission status Out-patient1.999941.213691.140.2530.61–6.57 In-patient Reference Age group Elderly3.3358982.765371.450.1460.66–16.94 Paediatric2.766543.1042160.910.3640.31–24.95 Adult Reference _constant1.495010.76401230.790.4310.55–4.07Number of observations = 95, LR chi2 (4) = 11.99, Prob > chi2 = 0.0174, Pseudo R2 = 0.1392 Multivariate logistic regression analysis of associations between demographic variables and propensity for multidrug resistant uropathogens isolation Number of observations = 95, LR chi2 (4) = 11.99, Prob > chi2 = 0.0174, Pseudo R2 = 0.1392 Table 7Proportion of multidrug resistance per isolated uropathogen speciesBacteriological factorMDR-negative (n, %)MDR-positive (n, %)p-valueGram’s classificationGram Negative (n = 61)12 (19.7)49 (80.3) 0.324 Gram Positive (n = 34)4 (11.8)30 (88.2)Species of isolated uropathogensCitrobacter sp. (n = 17)4 (21.2)13 (78.8) 0.109 E. coli (n = 20)6 (14.5)14 (85.5)Enterobacter sp. (n = 5)0 (0.0)5 (100.0)Enterococcus sp. (n = 19)2 (10.5)17 (89.5)Klebsiella sp. (n = 9)0 (0.0)9 (100.0)Proteus sp. (n = 3)2 (66.7)1 (33.3)P. aeruginosa (n = 7)0 (0.0)7 (100.0)S. agalactiae (n = 3)1 (33.3)2 (66.7)S. aureus (n = 11)1 (9.1)10 (90.9)S. saprophyticus (n = 1)0 (0.0)1 (100.0)Total 16 (16.8) 79 (83.2) *Significance of comparison was determined by p-value < 0.05 Table 7Proportion of multidrug resistance per isolated uropathogen speciesBacteriological factorMDR-negative (n, %)MDR-positive (n, %)p-valueGram’s classificationGram Negative (n = 61)12 (19.7)49 (80.3) 0.324 Gram Positive (n = 34)4 (11.8)30 (88.2)Species of isolated uropathogensCitrobacter sp. (n = 17)4 (21.2)13 (78.8) 0.109 E. coli (n = 20)6 (14.5)14 (85.5)Enterobacter sp. (n = 5)0 (0.0)5 (100.0)Enterococcus sp. (n = 19)2 (10.5)17 (89.5)Klebsiella sp. (n = 9)0 (0.0)9 (100.0)Proteus sp. (n = 3)2 (66.7)1 (33.3)P. aeruginosa (n = 7)0 (0.0)7 (100.0)S. agalactiae (n = 3)1 (33.3)2 (66.7)S. aureus (n = 11)1 (9.1)10 (90.9)S. saprophyticus (n = 1)0 (0.0)1 (100.0)Total 16 (16.8) 79 (83.2) *Significance of comparison was determined by p-value < 0.05 Proportion of multidrug resistance per isolated uropathogen species *Significance of comparison was determined by p-value < 0.05 Discussion The burden of UTI remains significant in the Ghanaian context The UTI prevalence rate of 26.6% found in this study falls within the 20–80% previously-reported rates of UTI in some tertiary and secondary health facilities in Ghana [28–31]. This may be pointing to UTI remaining a significant infectious disease of concern in the West African country and may be signalling of how the propagating factors may not have been significantly mitigated over the years. Gram-negative bacteria continue to dominate common uropathogens isolated in cases of UTI The predominance of Gram-negative bacteria in UTIs is consistent with findings from studies in Ghana and other regions worldwide [5, 11, 31–34] This pattern is likely attributable to E. coli and other Gram-negative organisms that are normal residents of the large intestine and can colonize the urethral opening [35]. Indeed, studies indicate that in about 75% of UTI cases, the uropathogen isolated from urine can also be recovered from rectal specimens of the same individual [36]. Again, the high prevalence of UTI in females may be attributable to anatomical and physiological determinants such as a shorter urethra and its proximity to the rectum, increasing vulnerability to infection [35, 37]. This notwithstanding, the relatively high proportion of Gram-positive Enterococcus spp. observed in this study is likely attributable to the inclusion of patients with healthcare-associated factors, including hospitalization and catheter use, which have been known to favour the proliferation of Gram-positive uropathogens [38]. Shifting trends of antibiotic resistance in UTI towards 2nd generation cephalosporins High resistance of common uropathogens to penicillin antibiotics and 2nd generation cephalosporins like cefuroxime, especially by extended-spectrum Ꞵ-lactamase (ESBL) producing-bacteria has been previously reported patterns similar to those which were observed in this study [5, 21, 39, 40]. This could be attributed, among other possible factors, to the increased use and easy access of the general population to antibiotics in Ghana [41, 42]. The situation is likely exacerbated by the promotion of other factors that drive the development of antibiotic resistance in uropathogens such as late diagnosis and self-medication [33, 43, 44]. Limited public education on the appropriate use of antimicrobials among local populations has been highlighted in global studies as an additional contributing factor [45, 46]. On the other hand, the high resistance observed to ampicillin and nalidixic acid antibiotics observed in this study is consistent with national antimicrobial resistance trends in Ghana, which have previously reported how resistance to these commonly used first-line antibiotics remains widespread. In fact studies have reported resistance rates of as high as 100% for nalidixic acid and ampicillin in UTI cases in Ghana [15, 17]. These persistent challenges continue to threaten the effectiveness of available therapeutic options for UTIs, including imipenem found in this study. Evidence of multidrug resistance detected among common uropathogens and potential risk factors Multidrug resistance is a serious threat to good clinical outcomes for UTI treatment and management locally and globally. The relatively high rate of multidrug resistant uropathogens identified in this study, similar to others in Ghana, and elsewhere in Africa and the Asia-Pacific region [47, 48], affirms the precarious nature of the clinical phenomenon and thus the need for urgent intervention and action [5, 49, 50]. At the KATH and the few other tertiary hospitals in Ghana, the tested antibiotics in this study (including SXT, AMP and CN) comprise the first line array of antibiotics tested against uropathogens [47]. Therefore, more than 80% of isolated uropathogens being resistant to most of these antibiotics could spell an imminent future of limited treatment options for UTI. Also, in this study, MDR correlated with the sex of patients and this association was significant. Although UTIs were more prevalent among women in this study, males had a significantly higher risk of multidrug-resistant (MDR) infection compared to females. According to some findings, male UTIs are typically related to underlying urological abnormalities, such as prostatic enlargement or posterior urethral valves, conditions that frequently involve instrumentation and elevate infection risk [47, 51]. Other studies also posit this observation could be linked to behavioural characteristics such as non-adherence to prescription and guided treatment [5, 9, 47]. Some studies also suspect factors such as circumcision, urine stasis due to prolonged urine-holding, catheterization and frequency of sexual intercourse [34, 35, 47, 48, 51, 52]. Limitations of study While the study provides findings that may be important for clinical care and antimicrobial stewardship, some limitations encountered may affect the generalizability and applicability of the results. For instance, due to the operational nature of the study, the range of antibiotics tested was limited to those routinely tested and prescribed as first-line antibiotic regimen for UTI under the hospital’s treatment protocols and interpreted according to guidelines from CLSI 2020. Consequently, other relevant antibiotics within the same antimicrobial classes were not included in the susceptibility testing panel. The single-centre, cross-sectional design of this study, relatively small sample size, together with the random sampling strategy employed, may limit the generalizability of the findings to other health facilities and geographic regions in Ghana. The study could also have benefited from a more detailed assessment of patient-level risk factors if broader clinical data had been collected from participants whose samples were included. Such information would have strengthened multidrug resistance (MDR) surveillance and supported antimicrobial resistance (AMR) stewardship efforts. Furthermore, molecular investigations are warranted to characterize the specific multidrug resistance genes circulating within the population, which could help guide more effective treatment strategies and improve the clinical management of UTIs. Conclusion This study provides evidence that urinary tract infections remain an infectious disease of interest in Ghana—favouring mainly Gram-negative bacteria, particularly E. coli. Nevertheless, it hints at Gram positive uropathogens such as Enterococcus spp. dominating in hospital-acquired UTI. Of even greater concern is the threat posed by multidrug resistant uropathogens that cause these infections. Beside multidrug resistance, it also highlights the challenge of antimicrobial therapy for UTI; as a large proportion commonly-prescribed first-line antibiotics for UTI are less effective – especially ampicillin, nalidixic acid and trimethoprim-sulfamethoxazole antibiotics. Ultimately, this raises concerns for the treatment and management of UTI especially in an LMIC like Ghana. These thus strongly suggest the need for improved antimicrobial resistance stewardship practices as a measure of curbing this menace in resource-limited settings. This may include ensuring the judicious use of antibiotics in treatment and improved diagnostic stewardship in hospitals. Reducing turnaround times for urine investigations or providing informed empiric treatments are also some of the measures that can be employed. Given the propensity of hospital-acquired UTI playing a strong role in multidrug resistant-uropathogen spread, strict infection control and prevention (IPC) measures around the hospital may also help limit the spread of multidrug resistant bacteria among hospitalized patients. Supplementary Information Supplementary Material 1: Culture plates showing growth of different bacterial uropathogens isolated from urine on chromogenic agar. Supplementary Material 1: Culture plates showing growth of different bacterial uropathogens isolated from urine on chromogenic agar.